Immune cells · NK cells
NK cell therapy:
the body’s first responder.
Natural killer cells recognise and destroy tumour and virus-infected cells without prior sensitisation. Expanded in GMP labs and used as an oncology adjunct via registered clinical research at China’s Class A hospitals — $12,000–$30,000 all-in, graded honestly.
Innate
First-line defence
No prior sensitisation needed
Immunology
CD3-/CD56+
NK phenotype
Verified at batch release
GMP QC
Low
Immunogenicity
Some allogeneic / cord use possible
Clinical practice
$12–30k
Course all-in
Multi-infusion, vs $30–70k abroad
Industry data
Adjunct
Oncology role
Registered research, not a cure
NHC framework
Class A
All partner facilities
NMPA-licensed GMP cellular labs
NHC / NMPA
What they are
Innate, fast,
and broadly armed.
Natural killer cells are the immune system’s rapid responders. Where T-cells must first be trained against a specific antigen, NK cells recognise the general signs of a stressed, infected or cancerous cell and kill it directly — releasing perforin and granzymes that trigger the target’s death.
That broad reach is their strength. NK cells don’t need a tumour-specific target, so they complement antigen-specific approaches like CAR-T. Their low immunogenicity also means some cord-blood or donor NK products can be used across a family — an off-the-shelf advantage.
The honest limits matter too. NK function declines with age, and the research aim is to restore effective surveillance — but infusing NK cells into healthy people for “anti-ageing” is not validated. In China, NK therapy is used as an oncology adjunct through registered clinical research at Class A hospitals. See the full immune-cell guide.
Function
What NK cells do.
Immune defence
NK cells secrete perforin and granzymes to punch holes in and kill virus-infected and tumour cells directly — the body's rapid first response before adaptive immunity engages.
Immune surveillance
They continuously patrol for cells undergoing malignant transformation or stress, recognising and removing them before they establish — a key anti-cancer monitoring function.
Immune homeostasis
NK cells clear senescent and damaged cells and release regulatory cytokines that help keep the broader immune response balanced.
Antiviral activity
Active against virus-infected cells; investigational adjunct interest in chronic viral conditions, though evidence here remains early-stage.
Properties
Why NK cells are distinctive.
Broad-spectrum
NK cells target a wide range of abnormal cells without needing a specific tumour antigen — complementary to antigen-specific approaches like CAR-T.
Low immunogenicity
Lower rejection risk than many cell types means certain cord-blood or donor NK products can be shared within a family — an 'off-the-shelf' advantage.
Favourable safety
Generally well tolerated; transient fever/chills are the most common effect, with minimal marrow toxicity in autologous and cord-derived use.
Age-sensitive potency
NK function declines with age, so younger-sourced cells tend to be more active — one rationale behind banking immune cells earlier in life.
NK-cell therapy in China is delivered as registered clinical research (备案) at NMPA-licensed Class A hospitals, used principally as an oncology adjunct. It is not an NMPA-approved stand-alone drug and is not validated for healthy-person “immune boosting” or anti-ageing. We grade each case honestly.
The pathway
From blood draw
to infusion course.
Eligibility review
Senior oncologist reviews your records to confirm whether NK-cell adjunct therapy has supporting evidence for your case — or recommends a better-evidenced path. 5–7 business days.
Source & collection
NK cells are sourced from your peripheral blood (autologous) or matched cord blood / donor (allogeneic). On-site collection during your first days in China.
Expansion & QC
Cells are expanded and activated in a GMP lab (~2–3 weeks) and released only after passing viability, CD3-/CD56+ phenotype, sterility and endotoxin testing.
Infusion course
NK cells are infused intravenously as a course, with monitoring for transient infusion reactions. Often combined with standard oncology treatment per protocol.
Follow-up
Response tracked with imaging and labs; telehealth review with the operating physician and bilingual records throughout the 12-month follow-up window.
FAQ
NK cell therapy, answered.
- What are NK (natural killer) cells?
- NK cells are a core part of the innate immune system — the body's first line of defence. Unlike T-cells, they don't need prior sensitisation to a specific antigen; they recognise and kill stressed, virus-infected and tumour cells directly by releasing perforin and granzymes that trigger target-cell death. Their three classic roles are immune defence, immune surveillance (catching cells turning malignant) and immune homeostasis.
- How does NK cell therapy work?
- NK cells are isolated from peripheral blood (or cord blood), expanded and activated in a GMP lab over roughly 2–3 weeks, then re-infused intravenously. Because NK cells have low immunogenicity, certain allogeneic (donor / cord-blood) NK products can be used across family members without the rejection issues seen with other cell types. Younger-sourced NK cells are generally more active, which is one rationale for cell banking.
- Why do NK cells matter as we age?
- NK cell number can rise with age while their function declines — surveillance weakens, so abnormal and senescent cells are cleared less efficiently. This functional decline is associated with higher infection rates and cancer risk in older adults. The research interest in NK therapy is in restoring effective surveillance; however, infusing NK cells into healthy people purely for 'anti-ageing' is not validated by high-quality evidence, and we don't market it that way.
- What does NK cell therapy treat, and how strong is the evidence?
- NK-cell therapy is used principally as an adjunct in oncology supportive care — to support immune recovery and add anti-tumour pressure alongside standard treatment in selected patients. Evidence is moderate-to-emerging: some trials show benefit when NK infusions are added to chemotherapy or other immunotherapy, but NK therapy is not a stand-alone cure. In China it is delivered as registered clinical research at Class A hospitals, not as an approved drug.
- Is NK cell therapy safe?
- The safety profile of autologous and cord-derived NK infusions is favourable — they are generally well tolerated, with transient fever or chills around infusion being the most common effects, and minimal toxicity to normal bone marrow. As with all cell products, safety depends on the lab: NMPA-licensed GMP facilities perform release testing for viability, phenotype (CD3-/CD56+), sterility and endotoxin before any infusion.
- How much does NK cell therapy cost in China?
- All-in NK-cell courses including coordinator and on-site stay run roughly $12,000–$30,000, typically as a multi-infusion course. Pricing depends on hospital, cell dose, number of infusions and whether cells are autologous or allogeneic/cord-derived. Compared with $30,000–$70,000+ at premium clinics in Korea, Japan or the US, China combines regulated GMP facilities with materially lower cost.
- Can foreigners get NK cell therapy in China?
- Yes — through international departments at Class A hospitals running registered NK-cell research protocols. Panda Touring Care reviews eligibility (we screen out cases without supporting evidence), arranges the M-visa, on-site blood/cord collection, the infusion course and telehealth follow-up. We only partner with NMPA-licensed GMP facilities.
Continue exploring
Immune Cell Therapy
The full hub — NK, CIK, DC-CIK, CAPRI and CAR-T compared.
See all immune cellsCAR-T Therapy
Antigen-specific T-cell therapy — NMPA-approved for blood cancers.
Read on CAR-TCell Banking
Store NK and other immune cells while they're young and most potent.
Read on bankingCancer Treatment in China
Where NK adjuncts fit in a full oncology plan.
See oncologyStem Cell Therapy
MSC therapy for regeneration, autoimmune and orthopedic conditions.
Read on stem cellsCell Therapy Hub
Pillar overview across every cell category in China.
Back to hubCould NK therapy
support your treatment?
Submit your records and a senior oncologist will tell you honestly whether NK-cell adjunct therapy fits your diagnosis and which Class A hospital protocol is appropriate.